IP Library Granted Patent US 7,709,617
Granted Patent B2
US 7,709,617 · App. 11/173,983 · Granted May 4, 2010

Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,709,617
App. No.
11/173,983
Granted
May 4, 2010
Kind
B2
Abstract

The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the invention provide synergy between the therapeutic effects of immunostimulatory oligonucleotides and immunomer compounds in accordance with the invention, and the therapeutic effect of cytokine immunotherapy and/or chemotherapeutic agents and/or radiation.

Claims (7)

1. An immunostimulatory oligonucleotide having the structure 5′-TC TC TTG-X-GTT CT CT-5′; wherein X is a glycerol linker and  is 2′-deoxy-7-deazaguanosine.

2. A pharmaceutical formulation comprising the oligonucleotide according to claim 1 and a physiologically acceptable carrier.

3. A method for generating an immune response in a vertebrate, the method comprising administering to the vertebrate an immunostimulatory oligonucleotide having the structure 5′-TC TC TTG-X-GTT CT CT-5; wherein X is a glycerol linker and  is 2′-deoxy-7-deazaguanosine.

4. The method according to claim 3 , wherein the route of administration is selected from parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.

5. The oligonucleotide according to claim 1 , further comprising an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

6. The pharmaceutical composition according to claim 2 , further comprising an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

7. The method according to claim 3 , further comprising administering an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Nov 30, 2005
From: HYBRIDON, INC
To: IDERA PHARMACEUTICALS, INC
Reel/Frame 017240/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2005
From: KANDIMALLA, EKAMBAR R.; AGRAWAL, SUDHIR
To: HYBRIDON, INC.
Reel/Frame 017012/0369 →